

Edgar Filing: GENOMED INC - Form 8-K

GENOMED INC
Form 8-K
July 22, 2004

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):
JULY 19, 2004

GenoMed, INC.

(Exact name of registrant as specified in its charter)

FLORIDA	000-49720	43-1916702
-----	-----	-----
(State or other jurisdiction of incorporation)	(Commission file number)	(IRS Employer Identification Number)

9666 Olive Blvd., Suite 310, St. Louis, Missouri 63132

(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code:

(314) 652-0500

909 South Taylor Avenue, St. Louis, Missouri 63110

(Former name or former address if changed since last report)

ITEM 4. CHANGES IN REGISTRANT'S CERTIFYING ACCOUNTANT

- (b) Effective July 19, 2004, the registrant has engaged Rubin, Brown, Gornstein & Co. LLP ("RBG") of St. Louis, Missouri, to serve as its independent accountant to audit the registrant's financial statements.

The registrant has not consulted RBG regarding the application of accounting principles to a specific completed or contemplated transaction or the type of audit opinion that might be rendered on the registrant's financial statements, and no written or oral advice was provided by RBG on any such issue that was a factor considered by registrant in reaching a decision as to any accounting, auditing or financial reporting issue.

The registrant has not consulted RBG on any matter that was either the subject of a disagreement or a reportable event with regard to the

Edgar Filing: GENOMED INC - Form 8-K

registrant's prior auditors.

The registrant has provided a copy of the disclosure in this report to RBG and offered RBG the opportunity to furnish a letter to the Commission contemplated by Item 304(a)(2)(D) of Regulation S-K. RBG has advised that it does not intend to furnish such letter to the Commission.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

GenoMed, Inc.

Dated: July 22, 2004

By: /S/ David Moskowitz

Dr. David Moskowitz
Chairman of the Board and
Chief Executive Officer